Anti-Canine CD44 FITC 100 tests
- Known as:
- Antibody toCanine CD44 fluorecein 100 tests
- Catalog number:
- 11-5440-42
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Canine CD44 FITC 100 tests
Related genes to: Anti-Canine CD44 FITC 100 tests
- Gene:
- CD44 NIH gene
- Name:
- CD44 molecule (Indian blood group)
- Previous symbol:
- MIC4, MDU2, MDU3
- Synonyms:
- IN, MC56, Pgp1, CD44R, HCELL, CSPG8
- Chromosome:
- 11p13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2019-04-23
Related products to: Anti-Canine CD44 FITC 100 tests
Alkaline Phosphatase Conjugated Affinity Purified anti-Swine IgG (H&L) [Goat] Secondary_Antibodies#10 Rubber Bands, 1Lb Box Pale Crepe Gold#10 Rubber Bands, 1Lb Box Pale Crepe Gold#10 Rubber Bands, 1Lb Box Pale Crepe Gold(-)-Epigallocatechin gallate(-)-Epigallocatechin gallate (EGCG)(-)-JQ1(-)-Scopolamine Perchlorate (Hyoscine perchlorate)(d,l)-Tetrahydroberberine (Canadine)(d,l)_Tetrahydroberberine (Canadine)(Deamino_Phe19,D_Ala24,D_Pro26_(®)_Phe27)_GRP (19_27) (human, porcine, canine) Salt Trifluoroacetate Binding _ Synonym BW_10 SumFormula C57H72N14O8(Deamino_Phe19,D_Ala24,D_Pro26_(®)_Phe27)_GRP (19_27) (human, porcine, canine) Salt Trifluoroacetate Binding _ Synonym BW_10 SumFormula C57H72N14O8(Draxin) C1ORf187 FITC-conjugates: Drax-FITC Host: Rabbit Affinity purifed Related articles to: Anti-Canine CD44 FITC 100 tests
- To investigate the roles of the α2,3-sialyltransferase ST3Gal1 and the α2,6-sialyltransferase ST6Gal1 in T cell-mediated tumor control, we generated mice with mature T cell-specific deletion of ST3Gal1 (T-ST3KO) or ST6Gal1 (T-ST6KO) using distal Lck-Cre-mediated recombination. Deletion of ST3Gal1 in mature T cells did not affect thymic T cell development but resulted in a reduction of peripheral CD8+ T cells. In contrast, ST6Gal1 deletion had minimal impact on T cell development and peripheral T cell abundance. Following in vitro stimulation of isolated T cells from T-ST3KO and parental wild type (WT) mice with anti-CD3 plus anti-CD28/CD80-Fc, CD8+ T cells from T-ST3KO mice exhibited enhanced activation and an increased frequency of CD44 positive memory-like T cells, while comparison of T cells from T-ST6KO and the parental WT mice showed no significant changes. Despite the activated CD8+ T cell phenotype in T-ST3KO mice, subcutaneous MC38 tumors displayed accelerated growth. In contrast, tumor progression in T-ST6KO mice was unchanged from the parental WT mice. Notably, T-ST6KO mice developed increased pulmonary metastases following intravenous challenge with B16F10 melanoma cells, whereas metastatic burden was unaffected in T-ST3KO mice. These findings demonstrate distinct and non-redundant roles for ST3Gal1- and ST6Gal1-mediated sialylation in regulating T cell function and antitumor immunity and reveal context-dependent effects of T-cell intrinsic sialylation in controlling primary tumor growth and metastatic dissemination. - Source: PubMed
Publication date: 2026/08/19
Wang XiaoshuangPaulson James C - Glioblastoma (GBM) is the most common adult primary brain malignancy. Recent studies demonstrate that temozolomide (TMZ) facilitates the persistence of quiescent glioma stem cells (GSCs), which are responsible for GBM recurrence. An ideal therapy should eradicate both proliferating cells and GSCs. Abexinostat (Abx), a histone deacetylase inhibitor, was identified through connectivity mapping to target the specific GBM signature. Here, we demonstrate the anti-proliferative effect of Abx on both differentiated cells and GSCs. - Source: PubMed
Publication date: 2026/08/19
Perumalsamy BalajiVengoji RaghupathyThiraviyam AnandRamireddy IndumatiYadav PoonamShah AshuMallya KavitaSalehi AfshinKumar SushilJain ManeeshPonnusamy Moorthy PBatra Surinder KShonka Nicole - Cancer stem cells (CSCs) drive chemoresistance, metastasis, and relapse in triple-negative breast cancer (TNBC), yet a comprehensive synthesis of targeted therapy evidence remains lacking. We systematically searched PubMed, Scopus, and Web of Science (2010-2025) and pooled effect sizes from 12 eligible studies (540 TNBC samples) using a random-effects model per PRISMA 2020 guidelines. CSC-targeted therapies significantly reduced CSC viability (SMD = -1.12; 95% CI: -1.45 to -0.79; p < 0.001), with combination approaches showing superior efficacy, moderate heterogeneity (I = 52%), and no publication bias, supporting further clinical trials to validate these promising preclinical strategies. - Source: PubMed
Publication date: 2026/08/19
Rebai OlfaAmri MohamedFattouch Sami - Alveolar microenvironment-driven macrophage polarization critically influences chronic obstructive pulmonary disease (COPD) progression. Nuclear factor erythroid 2-related factor 2 (NRF2), a key transcription factor, regulates macrophage polarization, suppresses inflammation, and promotes cellular repair. However, its role in macrophage-mediated inflammation and metabolic regulation, particularly hyaluronic acid (HA)-related remodeling, remains incompletely defined. This study investigates a novel dimension of NRF2 in COPD pathogenesis through macrophage-specific modulation, aiming to uncover its previously unrecognized mechanism. - Source: PubMed
Publication date: 2026/08/14
Bai GeWang JiaqiWen QianmeiHuang YuningLi HaiqingXu YanhuiLiu YiyiYi ErkangWu FanCui JiedaMei XinyueZhang YuxiaZhou YuminSun RuitingRan Pixin - Oral squamous cell carcinoma (OSCC) remains highly lethal and is driven, in part, by chronic NF-κB-mediated inflammation. Sorafenib, a multikinase inhibitor of RAF/VEGFR/PDGFR, can suppress these pathways, but its clinical utility is limited by hydrophobicity, toxicity, and poor tumor penetration. We engineered hyaluronic acid-coated niosomes encapsulating sorafenib (SOR@Nio/HA) to enable CD44-targeted delivery to OSCC cells. - Source: PubMed
Wu TingLi YongshuoWang ZixianGuo Bin